SCHEMBL608271

SCHEMBL608271

OC(CN1CCN(Cc2ccc(F)cc2)CC1)Cn1c2ccccc2c2cc(-c3cccs3)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
GAA P10253 1/20 0.58
MAPK1 P28482 3/20 0.54
HTT P42858 3/20 0.54
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAD52 P43351 2/20 0.46
POLB P06746 2/20 0.46
ATM Q13315 1/20 0.44
DNM1 Q05193 2/20 0.44
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
HTR2A P28223 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606533 0.87 LMNA (0.68) LMNAGAAMAPK1HTTMAPT
SCHEMBL608732 0.86 LMNA (0.59) LMNAGAAMAPK1HTTMAPT
SCHEMBL608283 0.84 LMNA (0.81) LMNAGAAMAPK1HTTMAPT
SCHEMBL5024631 0.83 LMNA (0.57) LMNAGAAMAPK1HTTMAPT
SCHEMBL608269 0.83 LMNA (0.67) LMNAGAAMAPK1HTTMAPT
SCHEMBL607069 0.82 LMNA (0.60) LMNAGAAMAPK1HTTMAPT
SCHEMBL607210 0.82 MEN1 (0.69) LMNAGAAMAPK1HTTMAPT
SCHEMBL7673739 0.77 MAPT (0.36) LMNAGAAMAPK1HTTMAPT
SCHEMBL605834 0.76 BAX (0.63) LMNAGAAMAPK1HTTMAPT
SCHEMBL5022852 0.76 BAX (0.63) LMNAGAAMAPK1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD LMNA 55/4885GAA 926/4885MAPK1 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.